Logo image of MIRM

MIRUM PHARMACEUTICALS INC (MIRM) Stock Fundamental Analysis

NASDAQ:MIRM - Nasdaq - US6047491013 - Common Stock - Currency: USD

52.45  -0.71 (-1.34%)

After market: 52.45 0 (0%)

Fundamental Rating

3

Overall MIRM gets a fundamental rating of 3 out of 10. We evaluated MIRM against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of MIRM have multiple concerns. While showing a medium growth rate, MIRM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MIRM has reported negative net income.
In the past year MIRM has reported a negative cash flow from operations.
MIRM had negative earnings in each of the past 5 years.
MIRM had a negative operating cash flow in each of the past 5 years.
MIRM Yearly Net Income VS EBIT VS OCF VS FCFMIRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

The Return On Assets of MIRM (-14.94%) is better than 82.77% of its industry peers.
The Return On Equity of MIRM (-43.02%) is better than 69.98% of its industry peers.
Industry RankSector Rank
ROA -14.94%
ROE -43.02%
ROIC N/A
ROA(3y)-30.74%
ROA(5y)-34.18%
ROE(3y)-77.04%
ROE(5y)-66.29%
ROIC(3y)N/A
ROIC(5y)N/A
MIRM Yearly ROA, ROE, ROICMIRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

MIRM's Gross Margin of 72.68% is amongst the best of the industry. MIRM outperforms 84.19% of its industry peers.
MIRM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIRM Yearly Profit, Operating, Gross MarginsMIRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

3

2. Health

2.1 Basic Checks

MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MIRM has been increased compared to 1 year ago.
MIRM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MIRM is higher compared to a year ago.
MIRM Yearly Shares OutstandingMIRM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
MIRM Yearly Total Debt VS Total AssetsMIRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

MIRM has an Altman-Z score of 2.68. This is not the best score and indicates that MIRM is in the grey zone with still only limited risk for bankruptcy at the moment.
MIRM has a Altman-Z score of 2.68. This is in the better half of the industry: MIRM outperforms 73.00% of its industry peers.
MIRM has a Debt/Equity ratio of 1.33. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of MIRM (1.33) is worse than 81.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.33
Debt/FCF N/A
Altman-Z 2.68
ROIC/WACCN/A
WACC9.33%
MIRM Yearly LT Debt VS Equity VS FCFMIRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.34 indicates that MIRM has no problem at all paying its short term obligations.
MIRM has a worse Current ratio (3.34) than 60.21% of its industry peers.
A Quick Ratio of 3.15 indicates that MIRM has no problem at all paying its short term obligations.
The Quick ratio of MIRM (3.15) is worse than 61.10% of its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 3.15
MIRM Yearly Current Assets VS Current LiabilitesMIRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.99% over the past year.
Looking at the last year, MIRM shows a very strong growth in Revenue. The Revenue has grown by 112.12%.
EPS 1Y (TTM)52.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.37%
Revenue 1Y (TTM)112.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%89.37%

3.2 Future

Based on estimates for the next years, MIRM will show a very strong growth in Earnings Per Share. The EPS will grow by 29.13% on average per year.
MIRM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.87% yearly.
EPS Next Y59.05%
EPS Next 2Y35.71%
EPS Next 3Y28.39%
EPS Next 5Y29.13%
Revenue Next Year80.87%
Revenue Next 2Y51.35%
Revenue Next 3Y41.34%
Revenue Next 5Y37.87%

3.3 Evolution

MIRM Yearly Revenue VS EstimatesMIRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
MIRM Yearly EPS VS EstimatesMIRM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MIRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MIRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRM Price Earnings VS Forward Price EarningsMIRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRM Per share dataMIRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

MIRM's earnings are expected to grow with 28.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.71%
EPS Next 3Y28.39%

More info and screens

0

5. Dividend

5.1 Amount

MIRM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIRUM PHARMACEUTICALS INC

NASDAQ:MIRM (2/21/2025, 8:00:01 PM)

After market: 52.45 0 (0%)

52.45

-0.71 (-1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-05 2025-03-05/amc
Inst Owners104.19%
Inst Owner Change0.52%
Ins Owners2.11%
Ins Owner Change0.19%
Market Cap2.52B
Analysts86.25
Price Target63.95 (21.93%)
Short Float %16.34%
Short Ratio14.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.3%
Min EPS beat(2)-7.94%
Max EPS beat(2)34.54%
EPS beat(4)1
Avg EPS beat(4)-37.55%
Min EPS beat(4)-166.28%
Max EPS beat(4)34.54%
EPS beat(8)4
Avg EPS beat(8)-32.13%
EPS beat(12)7
Avg EPS beat(12)-64.94%
EPS beat(16)8
Avg EPS beat(16)-69.99%
Revenue beat(2)2
Avg Revenue beat(2)4.75%
Min Revenue beat(2)1.46%
Max Revenue beat(2)8.03%
Revenue beat(4)3
Avg Revenue beat(4)1.65%
Min Revenue beat(4)-3.29%
Max Revenue beat(4)8.03%
Revenue beat(8)7
Avg Revenue beat(8)8.49%
Revenue beat(12)9
Avg Revenue beat(12)1.82%
Revenue beat(16)10
Avg Revenue beat(16)17.78%
PT rev (1m)-0.48%
PT rev (3m)1.95%
EPS NQ rev (1m)13.83%
EPS NQ rev (3m)15.48%
EPS NY rev (1m)2.34%
EPS NY rev (3m)12.76%
Revenue NQ rev (1m)1.26%
Revenue NQ rev (3m)8.81%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)5.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.2
P/FCF N/A
P/OCF N/A
P/B 10.85
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.02
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS6.4
BVpS4.83
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.94%
ROE -43.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.68%
FCFM N/A
ROA(3y)-30.74%
ROA(5y)-34.18%
ROE(3y)-77.04%
ROE(5y)-66.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 1.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 112.62%
Cap/Sales 8.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.34
Quick Ratio 3.15
Altman-Z 2.68
F-Score4
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)1121.45%
Cap/Depr(5y)727.71%
Cap/Sales(3y)36.84%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.37%
EPS Next Y59.05%
EPS Next 2Y35.71%
EPS Next 3Y28.39%
EPS Next 5Y29.13%
Revenue 1Y (TTM)112.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%89.37%
Revenue Next Year80.87%
Revenue Next 2Y51.35%
Revenue Next 3Y41.34%
Revenue Next 5Y37.87%
EBIT growth 1Y13.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.99%
EBIT Next 3Y29.86%
EBIT Next 5YN/A
FCF growth 1Y80.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y98.97%
OCF growth 3YN/A
OCF growth 5YN/A